Doctor Concetta Crivera

Janssen Scientific Affairs, LLC, Raritan, NJ (United States of America)

Follow

Contributor content

Risk of venous thromboembolism recurrences in patients who continued versus discontinued rivaroxaban therapy after an initial six-month therapy

Presentation

Risk of venous thromboembolism recurrences in patients who continued versus discontinued rivaroxaban therapy after an initial six-month therapy

ESC 365 is supported by

novartis

Explore sponsored resources